|
|
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and three in phase I.
Number of employees : 1 300 people.
|
|
|
| 2019 | 2020 | Delta | | USD (in Million) | % | USD (in Million) | % | | Transformative Medicines | 60.21 | 100% | 803.40 | 100% | +1234.34% |
|
|
|
| 2020 | | USD (in Million) | % | | United States | 764.53 | 95.2% | | Rest of World | 38.87 | 4.8% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
401,527,789 |
362,619,946 |
90.3% |
0 |
0.0% |
90.3% |
|
|
|
| Name | Equities | % | | Baillie Gifford & Co. | 45,337,764 |
11.3% | | Stéphane Bancel | 22,715,594 |
5.66% | | Flagship Pioneering | 20,581,016 |
5.13% | | The Vanguard Group, Inc. | 18,204,552 |
4.53% | | Robert Langer | 11,509,357 |
2.87% | | BlackRock Fund Advisors | 7,598,007 |
1.89% | | Thélème Partners LLP | 6,302,056 |
1.57% | | SSgA Funds Management, Inc. | 6,008,874 |
1.50% | | Fidelity Management & Research Co. LLC | 5,550,272 |
1.38% | | Morgan Stanley Investment Management, Inc. | 3,910,621 |
0.97% |
|
|
|
|
- - Nasdaq Global Select Market - Nasdaq 100 / |
|
|
|
|
| - Bloomberg Code : |
|
| - Reuters Code : |
MRNA.O |
| - Datastream Code : |
|
|
| Company contact information |
|
Moderna, Inc. 200 Square Technology MA 02139 Cambridge, Massachusetts Phone : +1 617 714 6500 Fax : +1 617 583 1998 web site : https://www.modernatx.com |
|
|
|
Samsung BioLogics shares ease after jumping on vaccine deal |
Sector Other Biotechnology & Medical Research
Connections : Moderna, Inc. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
